MTHFD2 and neoplasm: High levels of MTHFD2 have been associated with tumor recurrence and worse prognosis in multiple solid and liquid malignancies and participate in resistance against gemcitabine and pemetrexed [18,19,21,22,23,24,25,26,27,28].